[go: up one dir, main page]

PE20091485A1 - DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS - Google Patents

DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS

Info

Publication number
PE20091485A1
PE20091485A1 PE2009000162A PE2009000162A PE20091485A1 PE 20091485 A1 PE20091485 A1 PE 20091485A1 PE 2009000162 A PE2009000162 A PE 2009000162A PE 2009000162 A PE2009000162 A PE 2009000162A PE 20091485 A1 PE20091485 A1 PE 20091485A1
Authority
PE
Peru
Prior art keywords
alkyl
phenyl
pyrrolo
metan
pyrimidin
Prior art date
Application number
PE2009000162A
Other languages
English (en)
Inventor
Christoph Gaul
Marc Gerspacher
Philipp Holzer
Carole Pissot Soldermann
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739330&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091485(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20091485A1 publication Critical patent/PE20091485A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

REFERIDA A UN COMPUESTO PIRROLO-PIRIMIDINA DE FORMULA (I), DONDE R1 ES HETEROCICLILO BICICLICO, TRICICLICO O ESPIROCICLICO DE 3 A 24 MIEMBROS, ARILO C6-C14, CICLOALQUILO DE 3 A 12 MIEMBROS, ENTRE OTROS; R2 ES H, HALOGENO, ALQUILO C1-C7, ENTRE OTROS; R3, R2a Y R3a SON H, HALOGENO, ALQUILO C1-C7, ENTRE OTROS; R4 ES -[C(R5)(R5)]n-R8, -CN, -C(=O)-R5, ENTRE OTROS; R5 ES H, ALQUILO C1-C7, HALOALQUILO C1-C7, ENTRE OTROS; R8 ES ALQUILO C1-C7, OH, ALQUIL-OXILO C1-C7, ENTRE OTROS; R10 ES H, ALQUILO C1-C7, HALO-ALQUILO C1-C7, ENTRE OTROS; n ES 0, 1 O 2. SON COMPUESTOS PREFERIDOS: (3,4-DIETOXI-FENIL)-[7-(4-METAN-SULFONIL-FENIL)-7H-PIRROLO-[2,3-d]-PIRIMIDIN-2-IL]-AMINA, (4-ISOPROPOXI-FENIL)-[7-(4-METAN-SULFONIL-FENIL)-7H-PIRROLO-[2,3-d]-PIRIMIDIN-2-IL]-AMINA, (4-ISOPROXI-FENIL)-[7-(4-METAN-SULFONIL-FENIL)-7H-PIRROLO-[2,3-d]-PIRIMIDIN-2-IL]-AMINA, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UN METODO DE PREPARACION. DICHOS COMPUESTOS INHIBEN LA ACTIVIDAD DE CINASA DE TIROSINA DE LAS CINASAS JANUS TALES COMO CINASA JAK2 Y/O CINASA JAK 3 Y SON UTILES EN EL TRATAMIENTO DE ENFERMEDADES PROLIFERATIVAS TALES COMO TUMORES, CANCER, LEUCEMIAS, ENTRE OTRAS
PE2009000162A 2008-02-06 2009-02-04 DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS PE20091485A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08151137 2008-02-06

Publications (1)

Publication Number Publication Date
PE20091485A1 true PE20091485A1 (es) 2009-10-26

Family

ID=39739330

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000162A PE20091485A1 (es) 2008-02-06 2009-02-04 DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS

Country Status (27)

Country Link
US (1) US8420657B2 (es)
EP (1) EP2247591A1 (es)
JP (1) JP5323095B2 (es)
KR (2) KR101277823B1 (es)
CN (1) CN101981036B (es)
AR (1) AR070558A1 (es)
AU (1) AU2009211338B2 (es)
BR (1) BRPI0908433A2 (es)
CA (1) CA2714177A1 (es)
CL (1) CL2009000255A1 (es)
CO (1) CO6321262A2 (es)
CR (1) CR11614A (es)
DO (1) DOP2010000242A (es)
EA (1) EA017952B1 (es)
EC (1) ECSP10010463A (es)
IL (1) IL207224A0 (es)
MA (1) MA32134B1 (es)
MX (1) MX2010008719A (es)
NI (1) NI201000137A (es)
NZ (1) NZ587271A (es)
PA (1) PA8815201A1 (es)
PE (1) PE20091485A1 (es)
SM (1) SMP201000104B (es)
TW (1) TW200938202A (es)
UY (1) UY31631A1 (es)
WO (1) WO2009098236A1 (es)
ZA (1) ZA201005338B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
WO2009114533A2 (en) * 2008-03-10 2009-09-17 Cornell University Modulation of blood brain barrier permeability
CA2734802C (en) * 2008-08-22 2016-05-31 Novartis Ag Pyrrolopyrimidine compounds as cdk inhibitors
US8518933B2 (en) * 2009-04-23 2013-08-27 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
US8546377B2 (en) 2009-04-23 2013-10-01 Abbvie Inc. Modulators of 5-HT receptors and methods of use thereof
ES2573696T3 (es) * 2009-04-23 2016-06-09 Abbvie Inc. Moduladores de receptores de 5-HT y sus métodos de uso
CA2775009A1 (en) * 2009-10-20 2011-04-28 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors
NZ600161A (en) * 2009-12-01 2014-08-29 Abbvie Inc Novel tricyclic compounds
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UY33227A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina como inhibidores de la cdk4/6
UY33226A (es) * 2010-02-19 2011-09-30 Novartis Ag Compuestos de pirrolopirimidina deuterada como inhibidores de la cdk4/6
SG184989A1 (en) 2010-04-30 2012-11-29 Cellzome Ltd Pyrazole compounds as jak inhibitors
TW201204732A (en) 2010-07-09 2012-02-01 Leo Pharma As Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
JP2013534233A (ja) * 2010-08-20 2013-09-02 セルゾーム リミティッド 選択的ｊａｋ阻害剤としてのヘテロシクリルピラゾロピリミジン類似体
JP2013540748A (ja) * 2010-09-16 2013-11-07 コーネル ユニバーシティー 血液脳関門の透過性を調節するためのアデノシン受容体シグナル伝達の使用法
WO2012143320A1 (en) 2011-04-18 2012-10-26 Cellzome Limited (7h-pyrrolo[2,3-d]pyrimidin-2-yl)amine compounds as jak3 inhibitors
EA030465B1 (ru) 2011-07-01 2018-08-31 Новартис Аг Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака
EP2760863A1 (en) * 2011-09-20 2014-08-06 Cellzome Limited Pyrazolo[4,3-c]pyridine derivatives as kinase inhibitors
EP2780017A1 (en) * 2011-11-15 2014-09-24 Novartis AG Combination of a phosphoinositide 3-kinase inhibitor and a modulator of the janus kinase 2-signal transducer and activator of transcription 5 pathway
CN102627646A (zh) * 2012-03-19 2012-08-08 苏州四同医药科技有限公司 一种3-碘-5-溴-4,7-二氮杂吲哚的制备方法
CN102633802B (zh) * 2012-04-11 2014-03-19 南京药石药物研发有限公司 一种合成2-氯-7H-吡咯并[2,3-d]嘧啶的中间体及其制法
WO2013170671A1 (zh) * 2012-05-14 2013-11-21 华东理工大学 蝶啶酮衍生物及其作为egfr、blk、flt3抑制剂的应用
CN103059030B (zh) * 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
WO2014145576A2 (en) 2013-03-15 2014-09-18 Northwestern University Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer
WO2015143692A1 (en) * 2014-03-28 2015-10-01 Changzhou Jiekai Pharmatech Co., Ltd. Heterocyclic compounds as axl inhibitors
US9902730B2 (en) * 2014-05-01 2018-02-27 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
JP6541689B2 (ja) 2014-05-01 2019-07-10 ノバルティス アーゲー Ｔｏｌｌ様受容体７アゴニストとしての化合物および組成物
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
SI3773593T1 (sl) 2018-03-30 2024-08-30 Incyte Corporation Zdravljenje hidradenitisa suppurative z zaviralci jak
CN111484496B (zh) * 2019-01-29 2022-11-29 江苏开元药业有限公司 2-氨基-吡咯并嘧啶和吡唑并嘧啶类化合物及其制备方法和用途
US11136329B2 (en) 2019-05-08 2021-10-05 Vimalan Biosciences, Inc. JAK inhibitors
CN110305140B (zh) * 2019-07-30 2020-08-04 上海勋和医药科技有限公司 二氢吡咯并嘧啶类选择性jak2抑制剂
TW202122400A (zh) * 2019-08-08 2021-06-16 美商維瑪蘭生物科學公司 Jak抑制劑
GB201911868D0 (en) * 2019-08-19 2019-10-02 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
EP4027993A4 (en) * 2019-09-13 2023-09-20 The Broad Institute Inc. CYCLO-OXYGENASE 2 INHIBITORS AND THEIR USES
GB201914910D0 (en) * 2019-10-15 2019-11-27 Sentinel Oncology Ltd Pharmaceutical compounds
WO2023036252A1 (zh) * 2021-09-08 2023-03-16 希格生科（深圳）有限公司 吡咯并嘧啶类或吡咯并吡啶类衍生物及其医药用途
CN114957248B (zh) * 2022-05-09 2023-12-29 南开大学 一种吡咯并嘧啶化合物及其制备方法、药物组合物和应用
CN116813624B (zh) * 2023-06-29 2025-10-03 成都金瑞基业生物科技有限公司 一种jak2抑制剂的晶型及制备方法

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7917643B2 (en) * 1996-09-12 2011-03-29 Audible, Inc. Digital information library and delivery system
US20030074530A1 (en) * 1997-12-11 2003-04-17 Rupaka Mahalingaiah Load/store unit with fast memory data access mechanism
US6887224B2 (en) * 1998-06-15 2005-05-03 Ilse Rubio Close fitting leakage resistant feminine hygiene pad
TW505646B (en) 1998-06-19 2002-10-11 Pfizer Prod Inc Pyrrolo [2,3-d] pyrimidine compounds
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
WO2002076985A1 (en) * 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
ATE410429T1 (de) 2002-03-07 2008-10-15 Hoffmann La Roche Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
US7132221B2 (en) * 2003-09-12 2006-11-07 Headway Technologies, Inc. Method to print photoresist lines with negative sidewalls
US7532909B2 (en) * 2003-10-15 2009-05-12 Nextel Communications Inc. System and method for providing dedicated paging channels for walkie-talkie services
US7319102B1 (en) 2003-12-09 2008-01-15 The Procter & Gamble Company Pyrrolo[2,3-d]pyrimidine cytokine inhibitors
WO2005080393A1 (en) * 2004-02-14 2005-09-01 Irm Llc Compounds and compositions as protein kinase inhibitors
WO2005085253A1 (en) 2004-03-05 2005-09-15 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine derivatives
WO2005107760A1 (en) * 2004-04-30 2005-11-17 Irm Llc Compounds and compositions as inducers of keratinocyte differentiation
CA2577588C (en) * 2004-10-29 2013-09-10 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US20060122003A1 (en) * 2004-12-03 2006-06-08 Kim Jong H Portable golf swing position training aid kit
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
DE602006004844D1 (de) * 2005-02-03 2009-03-05 Vertex Pharma Pyrrolopyrimidine verwendbar als protein kinase inhibitoren
JP2006241089A (ja) 2005-03-04 2006-09-14 Astellas Pharma Inc ピロロピリミジン誘導体またはその塩
MX2007013715A (es) 2005-05-05 2008-01-28 Ardea Biosciences Inc Diaril-purinas, azapurinas y deazapurinas como inhibidores no nucleosidos de transcriptasa inversa para el tratamiento del virus de inmunodeficiencia humana.
US7749527B2 (en) 2005-05-24 2010-07-06 Wyeth Llc Gel compositions for control of ecto-parasites
CA2625109A1 (en) 2005-10-13 2007-04-19 Glaxo Group Limited Pyrrolopyrimidine derivatives as syk inhibitors
RS51843B (sr) 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. KONDENZOVANI BICIKLIČNI m TOR INHIBITORI
SI3184526T1 (sl) 2005-12-13 2019-03-29 Incyte Holdings Corporation Derivati pirolo(2,3-D)pirimidina kot inhibitorji Janus kinaze
CA2645434A1 (en) 2006-03-20 2007-09-27 Synta Pharmaceutical Corp. Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
JP4861772B2 (ja) * 2006-08-28 2012-01-25 富士通株式会社 移動体標定プログラム、該プログラムを記録した記録媒体、移動体標定装置、および移動体標定方法
CL2007002994A1 (es) 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
CL2008001709A1 (es) 2007-06-13 2008-11-03 Incyte Corp Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras.
KR20090033605A (ko) * 2007-10-01 2009-04-06 삼성전자주식회사 적층형 반도체 패키지, 그 형성방법 및 이를 구비하는전자장치
WO2009070524A1 (en) 2007-11-27 2009-06-04 Wyeth Pyrrolo[3,2-d]pyrimidine compounds and their use as pi3 kinase and mtor kinase inhibitors
KR20100095020A (ko) 2007-12-19 2010-08-27 암젠 인크 세포 주기 억제제로서의 융합된 피리딘, 피리미딘 및 트리아진 화합물
US20090192176A1 (en) 2008-01-30 2009-07-30 Wyeth 1H-PYRAZOLO[3,4-D]PYRIMIDINE, PURINE, 7H-PURIN-8(9H)-ONE, 3H-[1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE, AND THIENO[3,2-D]PYRIMIDINE COMPOUNDS, THEIR USE AS mTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES

Also Published As

Publication number Publication date
IL207224A0 (en) 2010-12-30
JP2011511034A (ja) 2011-04-07
UY31631A1 (es) 2009-09-30
JP5323095B2 (ja) 2013-10-23
MX2010008719A (es) 2010-09-24
CA2714177A1 (en) 2009-08-13
US8420657B2 (en) 2013-04-16
US20090203688A1 (en) 2009-08-13
KR20100119786A (ko) 2010-11-10
CR11614A (es) 2010-09-06
SMAP201000104A (it) 2010-11-12
CN101981036B (zh) 2013-09-04
NI201000137A (es) 2011-09-29
KR101277823B1 (ko) 2013-07-15
CL2009000255A1 (es) 2009-08-14
CO6321262A2 (es) 2011-09-20
TW200938202A (en) 2009-09-16
BRPI0908433A2 (pt) 2019-09-24
WO2009098236A1 (en) 2009-08-13
EA017952B1 (ru) 2013-04-30
EA201001242A1 (ru) 2011-08-30
AU2009211338A1 (en) 2009-08-13
EP2247591A1 (en) 2010-11-10
NZ587271A (en) 2012-03-30
MA32134B1 (fr) 2011-03-01
ECSP10010463A (es) 2010-10-30
DOP2010000242A (es) 2010-08-31
SMP201000104B (it) 2011-09-09
CN101981036A (zh) 2011-02-23
AR070558A1 (es) 2010-04-21
AU2009211338B2 (en) 2011-12-15
PA8815201A1 (es) 2009-09-17
KR20130066703A (ko) 2013-06-20
ZA201005338B (en) 2011-09-28

Similar Documents

Publication Publication Date Title
PE20091485A1 (es) DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS
PE20091468A1 (es) DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA
PE20091833A1 (es) Derivados heterociclicos espiro biciclicos o heterociclicos biciclicos, puenteados, de pirazolo [1,5-a]pirimidinas como inhibidores de quinasas raf y metodos para su preparacion
PE20140293A1 (es) Novedosos derivados heterociclicos
IL292229A (en) Pharmacological combination of prmt5 inhibitors
AR080785A1 (es) Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros.
CO6321235A2 (es) Analogos de carba-nucleosidos 1 sustituidos para el tratamiento antiviral
MX2024005335A (es) Proceso para la preparacion de derivados de 7h-pirrolo[2,3-d]pirim idina y sus intermedios sinteticos.
PE20110545A1 (es) Compuestos de triazolopiridina como inhibidores de jak
RU2014130125A (ru) Новые пиррольные соединения, способ их получения и фармацевтические композиции, содержащие их
PE20070752A1 (es) Triazolopiridazinas como moduladores de quinasa
TW200745113A (en) Sulphonamidoaniline derivatives being janus kinases inhibitors
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
PL1628685T3 (pl) Przeciwwirusowe analogi fosfonianowe
EA201170771A1 (ru) Органические соединения
PE20130012A1 (es) Derivados de pirazol como inhibidores de jak
PE20171514A1 (es) Heterociclos biciclicos como inhibidores de fgfr
PE20191105A1 (es) Inhibidores de moleculas pequenas de lafamilia de quinasas jak
UY35861A (es) ?acrilamidas de pirrolo[2,3-d]pirimidini lo, pirrolo[2,3-b]irazinilo y pirrolo[2,3-d]piridinilo?
ME02202B (me) Jedinjenja pirolopirimidina kao inhibitori cdk4/6
PE20170403A1 (es) COMPUESTOS DE IMIDAZO[4,5-c]QUINOLIN-2-ONA Y SU USO PARA TRATAR CANCER
NZ631187A (en) Tricyclic quinoline and quinoxaline derivatives
MX379425B (es) 7-bencil-4-(2-metilbencilo) -2,4,6,7,8,9-hexahidroimidazo [1,2-a] pirido [3,4-e] pirimidin-5 (1h) -ona, análogos y sales del mismo y su uso en terapia.
PE20180116A1 (es) HETEROCICLILMETIL-TIENOURACILO COMO AGONISTAS DEL RECEPTOR DE ADENOSINA A2b
RU2017140446A (ru) Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество

Legal Events

Date Code Title Description
FA Abandonment or withdrawal